Figure 5.
Summary of adverse events for patients treated with ibrutinib. Adverse events with prevalence ≥30% in all patients, excluding hypertension, are shown.
Summary of adverse events for patients treated with ibrutinib. Adverse events with prevalence ≥30% in all patients, excluding hypertension, are shown.
